Chimeric cytokine receptors in lymphocytes

Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

4352523, 4353201, 530350, 536 234, C07K 14715, C07K 1900, C12N 1562

Patent

active

057472920

DESCRIPTION:

BRIEF SUMMARY
TECHNICAL FIELD

The invention relates to the field of immunotherapy, more specifically to the introduction of genetic material encoding chimeric cytokine receptors into lymphocytes to reduce the dependency of the activated lymphocytes on T helper cells and/or growth factors supplied by T.sub.H -cells.


BACKGROUND

T lymphocytes are responsible primarily for protection against intracellular pathogens and malignant tumors. Individuals who are grossly deficient in T-cell immunity frequently succumb to overwhelming infections by organisms such as cytomegalovirus, Pneumocystis carinii, Candida, and other apparently "opportunistic" pathogens, including bacteria, viruses and fungi. Immunosuppression can result from a variety of causes, including viral infections (for example, with the HIV virus), as a result of chemical therapy, and malignancies (particularly of types that affect the hematopoietic system). T-cell immunity is also the major mechanism for rejection of allogeneic tissue or organ transplants. In fact, a major limitation to transplant therapy has been the difficulty in suppressing T-cell allograft rejection reactions without overly compromising vital protective mechanisms.
The adoptive transfer of antigen (Ag)-specific T cells to establish immunity appears to be an effective therapy for some viral infections and tumors in the mouse animal model system. (For a review, See P. D. Greenberg, in Advances in Immunology F. Dixon Ed. Academic Press, Inc. Orlando Fla. (1991), pp. 280-355.) However, the efficacy of an adoptive transfer method is dependent upon many factors, including the longevity of the transferred clones and the lack of toxicity to the host of the transferred cells.
Mature T lymphocytes generally express the CD3 cell surface molecule, but consist predominantly of two basic subtypes based on their mutually exclusive expression of cell surface molecules CD4 and CD8. CD4.sup.+ T cells are generally involved in "helper" functions in immune responses and secrete cytokine molecules, in particular interleukin 2 (IL-2), upon which the cytotoxic CD8.sup.+ T cells are dependent. CD4.sup.+ T cells are often referred to as T helper (T.sub.H) cells. CD8.sup.+ cells are involved in "effector" functions in immune responses, such as direct cytotoxic destruction of target cells bearing foreign antigens, and represent an important mechanism for resistance to viral infections and tumors. The functional distinction between CD4.sup.+ and CD8.sup.+ T cells is based on the ability of CD4.sup.+ cells to recognize antigen presented in association with class II MHC molecules, and CD8.sup.+ cells to recognize antigen presented in association with class I MHC molecules. The CD8.sup.+ cells that mediate this lytic function are designated cytotoxic T lymphocytes (CTLs). Although most CTL are of the CD8.sup.+ phenotype, some CTL of the CD4.sup.+ phenotype have been described. Generally, individual CTLs (whether CD8.sup.+ or CD4.sup.+) are antigen-specific.
Lymphocytes are dependent upon a number of cytokines for proliferation. For example, CTLs are dependent on helper T (T.sub.H) cell-derived cytokines, such as IL-2, for growth and proliferation in response to foreign antigens. (Zinkernagel and Doherty, Adv. Immunol. 27:51, 1979; Male et al., Advanced Immunology, Chap. 7, Gower Publ., London, 1987; Jacobson et al., J. Immunol. 133:754, 1984). IL-2, for example, is a potent mitogen for cytotoxic T lymphocytes (Gillis and Smith,. Nature 268:154, 1977), and the combination of antigen and IL-2 causes proliferation of primary CD8.sup.+ T cells in vitro. The importance of IL-2 for the growth and maintenance of the CD8.sup.+ CTL in vivo has been documented in models of adoptive immunotherapy in which the therapeutic efficacy of transferred anti-retroviral CD8.sup.+ cells is enhanced by subsequent administration of IL-2 (Cheever et al., J. Exp. Med. 155:968, 1982; Reddehase et al., J. Virol. 61:3102, 1987). IL4 and IL-7 are also capable of stimulating the proliferation of at least a sub-population of mature CD8.sup.+ CTL (Alders

REFERENCES:
patent: 5030576 (1991-07-01), Dull et al.
Hatakeyama et al., "Transmembrane signaling of interleukin 2 receptor" J. Exp. Med. (1987) 166:362-375.
Roussel et al., "Antibody-induced mitogenicity mediated by a chimeric CD2-c-fms receptor" Mol. Cell. Biol. (1990) 10:2407-2412.
Greenberg, P.D., "Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells" Advances in Immunology, Academic Press, Inc., (1991) pp. 280-355.
Zinkernagel et al., "MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness" Advances in Immunology, Academic Press, Inc., (1979) pp. 51-177.
Jacobson et al., "Measles virus-specific T4.sup.+ human cytotoxic T cell clones are restricted by class II HLA antigens" J. Immunol. (1984) 132(2):754-757.
Gillis et al., "Long term culture of tumour-specific cytotoxic T cells" Nature (1977) 268:154-156.
Cheever et al., "Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2" J. Exp. Med. (1977) 155:968-980.
Reddehase et al., "CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity" J. Virology (1987) 61(10):3102-3108.
Alderson et al. "Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood" J. Exp. Med. (1990) 172:577-587.
Rosenberg et al., "Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma" New Engl. J. Med. (1988) 319:1676-1680.
Walker et al., "HIV-specific cytotoxic T lymphocytes in seropositive individuals" Nature (1987) 328:345-348.
Plata et al., "AIDS virus-specific cytotoxic T lymphocytes in drug disorders" Nature (1987) 328:348-351.
Siliciano et al., "Analysis of host-virus interactions in AIDS with anti-gp120 T cell clones: effect of HIV sequence variation and a mechanism for CD4+ cell depletion" Cell (1988) 54:561-575.
Chenciner et al., "Multiple subsets of HIV-specific cytotoxic T lymphocytes in humans and in mice" Eur. J. Immunol. (1989) 19:1573-1544.
Walker et al., "Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1" Proc. Natl. Acad. Sci. USA (1989) 86:9514-9518.
Klarnet et al., "Helper-independent CD8.sup.+ cytotoxic T lymphocytes express IL-1 receptors and require IL-1 for secretion of IL-2" J. Immunol.(1989) 142(7):2187-2191.
Sprent et al. "Properties of purified T cell subsets" J. Exp. Med. (1985) 162:2068-2088.
Andrus et al., "Cytotoxic T cells both produce and respond to interleukin 2" J. Exp. Med. (1984) 59:647-652.
Klarnet et al., "Antigen-driven T cell clones can proliferate in vivo, eradicate disseminated leukemia, and provide specific immunologic memory" J. Immunol. (1987) 138(11):4012-4017.
Bernard et al., "High-affinity interleukin 2 binding by an oncogenic hybrid interleukin 2-epidermal growth factor receptor molecule" Proc. Natl. Acad. Sci. USA (1987) 84:2125-2129.
Takeshita et al., "Cloning of the .gamma. chain of the humal IL-2 receptor" Science (1992) 257:379-382.
Minamoto et al., "Characterization of the heterodimeric complex of human IL-2 receptor .alpha.-.beta. chains reconstituted in a mouse fibroblast cell line, L929" J. Immunol. (1990) 45(7):2177-2182.
von Boehmer et al., "LTY-2-T cell-independent functions of LYT-2.sup.+ cells stimulated with antigen or concanavalin A" H. Immunol. (1984) 133(1):59-64.
Mizuochi et al., "Role of Lymphokine-secreting CD8.sup.+ T cells in cytotixic T lymphocyte responses against vaccinia virus" J. Imnmunol. (1989) 142:270-273.
Izuhara et al., "The chimeric receptor between interleukin-2 receptor .beta. chain and interleukin-4 receptor transduces interleukin-2 signal" Biochemical and Biophysical Research Communications (1993) 190:992-1000.
Boshart et

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Chimeric cytokine receptors in lymphocytes does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Chimeric cytokine receptors in lymphocytes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric cytokine receptors in lymphocytes will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-52975

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.